# Establishment Labs Holdings Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Establishment Labs Holdings Inc).

## Overview

Establishment Labs Holdings Inc. develops and commercializes aesthetic and reconstructive breast implant products, centered on its Motiva Implants platform and related minimally invasive offerings. The company also manufactures its own products in Costa Rica and sells through distributors as well as direct relationships with physicians, hospitals, and clinics.

## Products & services

• Motiva Implants breast implants
• Motiva Flora SmoothSilk Tissue Expander
• Preservé minimally invasive breast enhancement
• Mia Femtech breast aesthetic procedures
• Qid Safety Technology RFID transponders

- **Breast implants** (75%) — Silicone breast implants sold for aesthetic augmentation and reconstruction.
- **Tissue expanders** (10%) — Temporary implantable devices used to prepare tissue for reconstruction.
- **Minimally invasive aesthetic products** (10%) — Products and procedures such as Preservé and Mia Femtech that broaden the portfolio beyond standard implants.
- **Safety and tracking technology** (5%) — RFID-based transponders and related technology used to support product identification and safety.

- Motiva Implants breast implants
- Motiva Flora SmoothSilk Tissue Expander
- Preservé minimally invasive breast enhancement
- Mia Femtech breast aesthetic procedures
- Qid Safety Technology RFID transponders

## Customers

The company sells primarily to medical distributors and directly to physicians, hospitals, and clinics that implant or stock its products. End demand is driven by plastic surgeons and other aesthetic or reconstructive providers serving patients seeking breast augmentation, revision, or reconstruction. Adoption depends on clinical differentiation, regulatory approvals, and physician confidence in safety and outcomes data.

- **Medical distributors** (primary) — Buy inventory for resale in approved markets and help the company reach fragmented international channels.
- **Physicians and plastic surgeons** (primary) — Purchase directly or use consigned inventory for breast augmentation and reconstruction procedures.
- **Hospitals and clinics** (secondary) — Stock products for surgical use, especially where consignment arrangements support procedure-based demand.
- **Aesthetic and reconstructive surgery centers** (secondary) — Adopt Motiva products to differentiate offerings and improve patient conversion and satisfaction.

- Medical distributors that resell implants into local healthcare markets
- Physicians and plastic surgeons buying directly for implantation
- Hospitals and clinics that stock consigned inventory for procedures
- Reconstructive surgery providers needing tissue expanders and implants
- Aesthetic practices seeking differentiated products to improve patient conversion

## Geography

The company sells in more than 100 countries and only began commercial U.S. sales in late 2024 after FDA approval of Motiva Implants. Manufacturing is concentrated in Costa Rica, where two ISO-13485-certified facilities support global supply and where the company also benefits from a tax holiday. Geography matters because revenue is exposed to foreign exchange, regulatory approvals, and market-by-market pricing pressure.

- Commercial sales span more than 100 countries
- U.S. market is newly opened and strategically important
- Manufacturing is concentrated in Costa Rica
- Costa Rica facilities support global supply and tax efficiency
- Foreign exchange and local regulation affect demand and margins

## Strategy

Management is focused on expanding U.S. sales, growing in existing international markets, and broadening the portfolio with minimally invasive products. The company is also using marketing, education, and selective acquisitions to improve patient conversion and strengthen its competitive position against larger implant makers.

- **U.S. commercialization** (short-term) — The U.S. is a large market and Motiva is newly approved there, creating a major growth runway.
- **International market expansion** (medium-term) — The company already sells in many countries and can leverage existing approvals and distributor relationships.
- **Portfolio broadening** (medium-term) — Minimally invasive products can widen the addressable market and reduce reliance on standard implants.
- **Commercial execution and brand building** (short-term) — Physician education and patient awareness are critical in a preference-driven aesthetic market.

- Expand U.S. revenues after FDA approval of Motiva Implants
- Grow in existing international markets with Motiva and new products
- Use social media, influencers, and education to improve conversion
- Add minimally invasive offerings such as Preservé and Mia Femtech
- Pursue acquisitions and distributor-network expansion where strategic

## Risks

The business faces regulatory, competitive, and commercialization risk because it depends on approvals, physician adoption, and continued market access across many jurisdictions. It also has meaningful financing and execution risk as a growth-stage medical device company with ongoing operating cash use and a need to scale manufacturing, sales, and working capital.

- **Regulatory approval delays or denials** [high] — The company needs approvals to commercialize new products and expand into new markets.
- **Competitive pressure from larger implant makers** [high] — Competitors have greater resources, broader relationships, and established distribution networks.
- **Pricing pressure in a price-sensitive market** [medium] — Aggressive discounting by competitors can force lower prices or reduce conversion rates.
- **Limited U.S. operating history** [medium] — The company has only recently begun U.S. commercial sales, so demand and execution are less proven.
- **Need for additional capital** [high] — Growth, commercialization, and manufacturing expansion may require external financing.

- FDA and foreign approvals can delay launches or limit market access
- Larger competitors have more resources, distribution, and pricing power
- U.S. commercialization is early, so execution risk remains elevated
- Pricing pressure can reduce margins in a price-sensitive implant market
- Foreign exchange and supply-chain disruptions can affect results

## Accounting

Revenue is recognized at shipment for most product sales, but consignment inventory is recognized only when the product is implanted, which can shift timing between periods. Results are also affected by foreign currency movements, seasonal demand, and manufacturing utilization, while Costa Rica tax incentives and capitalized facility investments can materially influence reported profitability and cash flow.

- **Revenue recognition for consignment sales** — Can shift revenue between periods and affect reported growth
- **Foreign currency translation and transaction effects** — Can materially affect revenue, gross margin, and operating results
- **Manufacturing capacity and depreciation** — Can pressure gross margin during expansion phases
- **Tax holiday in Costa Rica** — Can make tax expense unusually low versus normalized levels

- Revenue timing differs for shipment sales versus consignment inventory
- Foreign currency fluctuations can move reported revenue and gross margin
- Manufacturing utilization affects cost of revenue and gross margin
- Costa Rica tax holiday can materially reduce income tax expense
- Facility depreciation and startup costs affect margins as capacity ramps

---

*Last updated: 2026-09-24T11:47:05.902116+00:00*